In this white paper, best practices are described as well as required Sponsor/Local Representative agreement areas. It is important that major subject areas are agreed in order to ensure that the conduct of the clinical trial does not cause issues when the new drug application is assessed by the competent authorities. Although Local Representation applies to multiple areas of Pharmaceutical Development (Regulatory, Legal, etc.), this Whitepaper is limited to the area of Pharmacovigilance.
Explore related content and topics
Webinar
Practical Implementation of Signal Detection in Iterative Benefit Risk Evaluation
This webcast with PRA Health Sciences' Jacinta Aniagolu-Johnson (Senior Director, Safety and Risk Management) explores how a well defined signal…
White Paper
Transparency and Reliability
Adjudication can be a tool to improve the confidence of trial data, although it is essential to have a clear and defined process. Historically,…
Page
Pharmacovigilance & Patient Safety
We provide a comprehensive range of drug safety services, minimizing risk and protecting patient well-being from clinical development to…